The Diversion Blind Spot Nobody Is Auditing

Most diversion analytics platforms are built to monitor controlled substance activity. That's where the regulatory focus is, and that's where most dashboards direct attention. But what if an important diversion risk is hiding in a place few people review?In this Quick Take on Diversion Insights, Terri explores the often-overlooked world of cancel transactions and why they can represent a significant blind spot in diversion monitoring programs.This episode covers:• Why cancel transactions frequently go unreviewed• How non-controlled substance activity can be linked to diversion schemes• The risk of returning tampered medications to inventory• How non-controlled substances may be substituted for controlled substances• Why bedside clinical observations may not identify these events quickly• The importance of reviewing raw transaction logs, not just dashboard alerts• A real-world case where the warning signs were present in the data but initially overlookedFor diversion specialists, pharmacists, compliance professionals, medication safety teams, and healthcare leaders, this episode highlights an area that deserves greater attention in audit and monitoring strategies.Sometimes the most important clues aren't hidden—they're simply sitting in data that no one is reviewing.More from Rxpert Solutions:https://www.rxpert.solutions/